News about Express Scripts Holding Company, including commentary and archival articles published in The New York Times.

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

Healthcare management and administration service company Express Scripts is scheduled to report second-quarter results on Tuesday, July 28 after market close. With shares hitting all-time highs ...

Express Scripts Holding, a pharmacy benefit manager that negotiates drug prices for many health plans, will launch a formulary with lower list price drugs in an effort to reduce reliance on ...

Express Scripts Holding, a pharmacy benefit manager and specialty pharmacy that negotiates drug prices for 85 million people, plans to expand its full network offerings to "pharmacies ...

Express Scripts Holding Co. identified Friday several businesses, including a diabetes-testing-supply unit, that it plans to unload because they aren't core parts of the company's pharmacy-benefit ...

Express Scripts Holding Co. said it ended the contract with Walgreen because the drugstore operator wanted a premium compared to what Express Scripts paid other pharmacies.

Express Scripts Holding Co. defeated a bid by retail drugstores to suspend its $29.1 billion purchase of Medco Health Solutions Inc. while a lawsuit challenging the takeover is pending.

According to Express Scripts second quarter conference call, it's own integration challenges, including the shifting of customers to new systems, weighed down customer satisfaction rates last year.

BURLINGTON, NJ-Express Scripts Holding Co., which acquired Franklin Lakes, NJ-based Medco in a takeover last year, is seeking a $40-million tax credit under the state's Grow New Jersey program in ...

George Paz, who has led Express Scripts Holding Co. for a decade as CEO, will retire in May, the St. Louis County-based company announced Wednesday.

Express Scripts, the nation’s largest manager of prescriptions, has negotiated a “significant discount” for Viekira Pak, a new entrant to the expensive class of hepatitis C medications.